Migraines

NMT Medical, Inc. (NASDAQ: NMTI) nnounced that the Company is closing down its patent foramen ovale (PFO)/migraine trial, MIST II, to focus its resources on its PFO/stroke opportunity. The move is expected to save the Company approximately $14 million over the next two to three years as it redistributes investments originally budgeted for MIST II. As a result of this decision, NMT has ceased patient enrollment in MIST II, which was being conducted at 20 centers in the United States.

More: continued here

“Radiation from mobile phones delays and reduces sleep, and causes headaches and confusion, according to a new study”, reported The Independent on Sunday on January 20 2008. The Daily Telegraph also covered the story, reporting that a study funded by handset manufacturers found that using a mobile before going to bed could damage your health. The main health risk listed by the newspapers is less time in the deeper stages of sleep that can help the body recuperate.

More: continued here

“Radiation from mobile phones delays and reduces sleep, and causes headaches and confusion, according to a new study”, reported The Independent on Sunday on January 20 2008. The Daily Telegraph also covered the story, reporting that a study funded by handset manufacturers found that using a mobile before going to bed could damage your health. The main health risk listed by the newspapers is less time in the deeper stages of sleep that can help the body recuperate.

More: continued here

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, announced that it has completed the special protocol assessment (SPA) process with the U.S. Food and Drug Administration (FDA) for the first Phase 3 clinical trial of its MAP0004 product candidate, and has reached agreement with the Agency on the design of the protocol. The study, if successful, could support the potential approval of MAP0004 as a treatment for migraine.

More: continued here

POZEN Inc. (NASDAQ: POZN) announced that it has submitted the findings from the short-term human volunteer study of the genotoxic potential of Treximet? (formerly known as Trexima?) to the U.S. Food and Drug Administration (FDA).

More: continued here